MarketPulse

allergic reactions

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

ARS Pharmaceuticals to Report Q1 2026 Results as Neffy Commercialization Advances

ARS Pharmaceuticals ($SPRY) schedules May 15 earnings call to discuss Q1 2026 results and neffy® nasal spray commercialization progress across U.S., EU, and China markets.
SPRYFDA approvalanaphylaxis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aquestive to Unveil Anaphylm Clinical Results at 2026 Allergy Conference

Aquestive to present clinical trial data for Anaphylm, an investigational oral anaphylaxis treatment, at 2026 allergy conference, showing promising safety and efficacy results.
AQSTclinical dataFDA approval